Fritextsökning
Innehållstyper
-
Phase III win for Hansa Biopharma: “We Are Thrilled”
Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.
-
Explore the possibilities of the new ZEISS METROTOM 800 320 kV
Free ZEISS webinar July 10, 9:00-9:45 AM and 5:00-5:45 PM.
-
Organize and Manage Digital Classrooms
Create engaging lessons with ZEISS Labscope Teacher.
-
ZEISS Connected Quality: One metrology hub
The new product family ZEISS CONNECTED QUALITY is the solution for quick and secure data exchange, quality management and efficient system monitoring.
-
Agreement in the EU on eight years of data exclusivity for new medicines
New pharmaceuticals will be covered by eight years of data exclusivity, according to the proposed new pharmaceutical legislation that EU countries have now agre...
-
Plug and play lösning för ångfällor
Spirax Sarco har en kompakt "allt-i-ett"-lösning när det kommer till installation av ångfällor. Den kompakta lösningen är optimal eftersom du kan installera kul...
-
Discover Precision: Join ZEISS at the Control Fair in Stuttgart
May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.
-
Lovande data för borreliavaccin – ansökan kan lämnas in 2026
Franska vaccinspecialisten Valneva har rapporterat positiva fas II-data för vaccinkandidaten VLA15 mot borrelia som utvecklas tillsammans med Pfizer.
-
Virology professor on the threat from X: ”The next pandemic could be worse“
The question is not if, but when we will be affected by a new unknown virus that causes yet another pandemic. Are we sufficiently prepared? "Absolutely not!", r...
-
One System, Three Contrasting Techniques
ZEISS Axioscan 7 clinical - your digital slide scanner for diagnostics and clinical research.
-
New version of ISO 10993-1: the core standard for the biological evaluation of medical devices
ISO 10993-1, the core standard for the biological evaluation of medical devices, has been under revision over the past few years. A Final Draft International St...
-
Astra Zeneca’s asthma drug nears approval for sinus inflammation
Astra Zeneca’s drug Tezspire receives positive opinion from the European Medicines Agency (EMA) for the treatment of chronic rhinosinusitis with nasal polyps.
-
Security flaw in Swedish breast cancer screening software – woman passed away
A lack of safeguard in Sectra's software led to a woman with breast cancer receiving an incorrect diagnosis. She later passed away. The software is used in 20 o...
-
Genmab to Acquire Dutch biotech for USD 8 Billion
Danish pharmaceutical company Genmab has agreed to acquire Dutch firm Merus, a developer of cancer therapies, for USD 8 billion, equivalent to nearly SEK 75 billion.
-
Digitaliseringen förändrar vårt sätt att arbeta med ånga
Moderna ångsystem utsätts för större påfrestningar än någonsin tidigare, och även små avvikelser kan få stora konsekvenser för driften. Detta ställer helt nya k...
-
Problem hos kontraktstillverkare stoppar Regenerons blodcancerläkemedel
För andra gången har Regeneron nekats godkännande i USA för en ny lymfombehandling. Orsaken uppges denna gång vara anmärkningar mot en extern tillverkningsanläg...
-
Anna Törner: ”If I fall seriously ill, I’ll move to Finland”
”It is both undignified and undemocratic that cancer patients must travel to Finland to uphold a façade of fairness that does not truly exist”, Anna Törner writes in a column.
-
The FDA’s new transparency policy (Part 2)
In the second part of our article series on the FDA’s new “radical transparency” initiative, we explore regulatory strategies to navigate the potential impact o...
-
Karolinska Development tar in kapital – och byter namn
Life science-investmentbolaget Karolinska Development föreslår en företrädesemission om cirka 203 miljoner kronor före transaktionskostnader.
-
Svenskt biotechbolag tar in 153 miljoner till cancerstudie
One-carbon Therapeutics, ett svenskt biotechbolag med inriktning på svårbehandlad cancer, har tagit in 153 miljoner kronor i en övertecknad investeringsrunda.
-
Lundbeck kliver in i budstrid om narkolepsibolag
En budstrid har brutit ut om det irländska biotechbolaget Avadel Pharmaceuticals och dess potentiella storsäljare inom narkolepsi och hypersomni.
-
The top five most expensive drugs in 2025
New advanced therapeutic medicines are reaching the market, but their price tags remain exceptionally high. This year’s ranking of the most expensive drugs in t...
-
The FDA’s new transparency policy (Part 3)
As transparency and consistency become increasingly emphasized by the FDA, medical device manufacturers must approach their submissions with both thoroughness a...
-
Multiplex immunofluorescence chemistries with ZEISS tissue multiplexing workflow
Bringing leading multiplex immunofluorescence chemistries together in one automated 8-channel imaging platform.
BREAKING